Ibogaine TA is extracted directly from the root bark of Tabernanthe iboga, the sacred plant of Bwiti tradition native to Central West Africa. Ibogaine HCl, however, is predominantly semi-synthesized from voacangine isolated from Voacanga africana — a botanically related but distinct species in the Apocynaceae family. Though the active molecule is identical, these two botanical lineages yield medicines with fundamentally different pharmacological profiles.
Total Alkaloid extract is produced from the root bark of Tabernanthe iboga. The extraction process preserves the entire alkaloid matrix, ibogaine plus 12 or more companion compounds including ibogamine, tabernanthine, voacangine, coronaridine, and noribogaine.
Ibogaine content in TA varies significantly by batch, typically 8 to 33% depending on plant source, harvest maturity, and extraction method. A certificate of analysis (CoA) from an accredited laboratory is mandatory for every batch before clinical use. Without it, mg/kg dosing is impossible and safety cannot be assured.
Traditionally used in Bwiti ceremonies in West-Central Africa for centuries, TA is the "full-spectrum" preparation. The alkaloid synergy produces an entourage effect, broader receptor engagement and, in clinical observation, a richer visionary arc with more extended duration than HCl at equivalent ibogaine mg/kg.
Ibogaine HCl is ibogaine isolated and stabilized as a hydrochloride salt, typically 95 to 99% purity. The vast majority of clinical-grade HCl is semi-synthesized from voacangine, a structurally related indole alkaloid extracted from the bark and seeds of Voacanga africana — a tropical tree in the same Apocynaceae family as T. iboga, but far more abundant and sustainably harvested across West and Central Africa. The semi-synthetic conversion of voacangine to ibogaine via decarboxylation yields pharmaceutical-grade material without depleting endangered T. iboga populations.
The defining clinical advantage of HCl is dosing precision. Because purity is known and consistent, mg/kg calculations are straightforward and reproducible across patients and institutions. This makes HCl the formulation of choice for clinical research, protocol standardization, and patients where precise pharmacokinetic prediction is essential.
HCl produces a faster onset (30 to 60 min), shorter duration (18 to 36 hrs), and a more linear, introspective experience character compared to TA. Because only ibogaine is present, its cardiac effects. particularly hERG channel blockade and QTc prolongation, are well-characterized in the published literature and can be modeled predictively.
Twelve clinical factors, pharmacokinetics, safety, dosing, and clinical use. Both formulations are administered at MindScape under identical safety protocols.
| Factor | TA (Total Alkaloid) | HCl (Hydrochloride) |
|---|---|---|
| Purity | 8 to 33% ibogaine (batch-dependent) | 95 to 99% ibogaine |
| Other alkaloids | 12+ present (ibogamine, tabernanthine, voacangine…) | None, ibogaine only |
| Dosing precision | Requires assay certificate per batch | Precise by weight (minus ~15% salt) |
| Onset | 45 to 90 minutes | 30 to 60 minutes |
| Duration | 24 to 48 hours | 18 to 36 hours |
| Experience character | Fuller, more visionary, richer affect | Cleaner, more introspective, linear |
| Nausea profile | Higher, multiple alkaloids contribute | Moderate |
| Therapeutic breadth | Broader, alkaloid synergy (entourage effect) | Targeted, single-molecule |
| Cardiac considerations | Multiple alkaloids; full screening required | Well-characterized QTc effect; preferred with cardiac risk |
| Cost | Lower | Higher |
| Published research | Less standardized, batch variability limits RCTs | More published studies |
| Botanical source | Tabernanthe iboga root bark (Central West Africa) | Semi-synthesized from Voacanga africana (West/Central Africa) |
| Traditional use | Bwiti ceremonies, centuries of ceremonial use | Modern clinical/research setting |
Highlights indicate a relative advantage for that formulation in that factor. Formulation selection is always made by the MindScape medical team based on individual patient profile.
TA is not "ibogaine with impurities." It is a full-spectrum alkaloid matrix where each compound plays a distinct pharmacological role. The synergy between these alkaloids, analogous to the entourage effect documented in cannabis research, produces therapeutic characteristics no single-molecule preparation can replicate.
Primary psychoactive compound. Acts on serotonin transporters, opioid receptors, sigma-2, NMDA, and nicotinic systems. Drives visionary experience and acute neuroplastic cascade.
Long-acting metabolite present in TA and formed from ibogaine in vivo. Key driver of extended anti-craving effects and mood stabilization lasting weeks post-treatment.
Structural analog to ibogaine. Hypothesized to buffer cardiac and experiential effects in TA. producing the smoother profile reported versus equivalent HCl doses.
Serotonergic activity. Contributes to neuromodulatory breadth of the full-spectrum extract across the monoamine system.
Structural similarity to ibogaine. Documented cardiovascular and neurological activity in preclinical studies. Contributes to overall receptor engagement.
Anti-addictive properties in animal models. Believed to contribute to the durability of anti-craving effects seen with TA versus HCl-only protocols.
Minor alkaloid with emerging research interest. Part of the full-spectrum complexity believed to drive the entourage effect in TA.
On batch variability: TA ibogaine content ranges from 8 to 33% depending on plant genetics, growing region, harvest maturity, and extraction method. This is not a flaw. it is an inherent property of a natural full-spectrum extract. MindScape requires a third-party Certificate of Analysis (CoA) for every TA batch with exact ibogaine percentage, to calculate ibogaine-equivalent mg/kg precisely before any patient dose is administered.
MindScape is one of a small number of ibogaine centers worldwide that administers both authentic TA and pharmaceutical-grade HCl. Rather than defaulting to one formulation, our medical team selects and sequences each based on the individual patient's indication, cardiac profile, CYP2D6 metabolizer status, and treatment goals.
The most common protocol uses a TA flood dose for the primary treatment session, leveraging the broader alkaloid spectrum, extended duration, and entourage effect, followed by HCl boosters at precisely calculated mg/kg when supplemental dosing is indicated. The booster's exact pharmacokinetics allow the physician to add ibogaine equivalents with confidence during an already-active session.
Some protocols use HCl exclusively. particularly for patients with cardiac risk factors where the well-characterized single-molecule safety profile is preferred, or for opioid use disorder cases where rapid, precise withdrawal interruption is the primary goal.
Protocol Documentation. Every Dose
The initial flood dose at MindScape is most commonly administered as TA. The full alkaloid spectrum engages multiple receptor systems simultaneously, serotonin, opioid, sigma-2, NMDA, and nicotinic, driving the comprehensive neuroplastic cascade that ibogaine is known for.
The extended duration (24 to 48 hours) and broader alkaloid profile are particularly valuable for complex addiction cases, neurological indications, and spiritual/transformational protocols where depth of experience is therapeutically significant.
When a booster dose is clinically indicated, typically 4 to 8 hours into the primary session. HCl allows the physician to add an exact ibogaine-equivalent in mg/kg without introducing additional alkaloid variables. The math is clean. The effect is predictable.
HCl boosters are also used in standalone repeat sessions where the goal is targeted symptom relief rather than a full transformational arc, for example, in a Parkinson's protocol designed to re-dose at defined symptom recurrence thresholds.
Ibogaine is metabolized primarily by the CYP2D6 enzyme. Poor metabolizers (7 to 10% of the population) cannot efficiently convert ibogaine to noribogaine, resulting in higher plasma concentrations at any given dose, for both TA and HCl.
MindScape tests or documents CYP2D6 status for every patient. Poor metabolizers receive a 30 to 50% dose reduction as standard protocol. Ultra-rapid metabolizers may require adjusted timing. This single variable accounts for a disproportionate share of adverse events at facilities that do not test for it.
Ibogaine dosing is not a weight-based table. The formulation, batch purity, CYP2D6 genotype, and clinical indication all determine the appropriate ibogaine-equivalent dose. Here is exactly how MindScape calculates it.
Because TA potency varies by batch, the raw amount administered must be converted to ibogaine-equivalent using the assay certificate percentage.
Example: 2,000 mg TA with 20% assay in a 70 kg patient = 400 mg ibogaine equivalent = 5.7 mg/kg ibogaine equivalent.
HCl purity is typically 95 to 99%. The hydrochloride salt itself accounts for approximately 15% of the molecular weight, so raw mg slightly overstates the free-base ibogaine delivered.
Example: 1,200 mg HCl in a 70 kg patient = ~1,020 mg ibogaine free base equivalent = 14.6 mg/kg.
Ibogaine-Equivalent Target Ranges by Indication (mg/kg)
Ranges are clinical guidelines, not prescriptions. Actual doses are individualized by the MindScape physician based on patient-specific factors.
Both TA and HCl prolong the cardiac QTc interval. Neither is safe without rigorous pre-screening and continuous monitoring. MindScape applies identical safety infrastructure regardless of formulation.
Ibogaine blocks hERG potassium channels, which extends the cardiac QT interval. In patients with underlying risk factors, this can create conditions for life-threatening arrhythmia. MindScape monitors QTc at baseline and every 30 minutes throughout the acute treatment phase.
Our escalation protocol triggers when QTc exceeds 500ms or rises more than 60ms above each patient's personal baseline, not a population average. TA may carry additional cardiac effects from companion alkaloids beyond ibogaine alone; this is reflected in our monitoring frequency, which does not change based on formulation.
For patients with QTc prolongation at baseline, structural cardiac disease, arrhythmia history, or concomitant QT-prolonging medications, HCl is preferred over TA. The single-molecule pharmacology allows more accurate QTc effect modeling from pre-existing research data.
TA's additional alkaloids. while potentially beneficial therapeutically , introduce additional cardiac unknowns that are not fully characterized in the published literature. We apply the precautionary principle for patients with elevated baseline cardiac risk.
Every TA batch requires a Certificate of Analysis from an accredited analytical chemistry laboratory before clinical use at MindScape. The CoA must specify ibogaine percentage (and ideally the full alkaloid profile). Batches without documented assay are not administered , dosing safety cannot be established without it.
HCl requires a purity certificate from the supplier. MindScape also records batch ID, supplier name, and lot number for every HCl administration, enabling retrospective pharmacovigilance if any adverse trend is identified across batches.
All patients, regardless of formulation, complete a 12-lead ECG, complete blood panel, metabolic panel, CYP2D6 genotype testing, and comprehensive medication review before any ibogaine is administered. Drug-drug interactions, particularly with QT-prolonging medications and CYP2D6 inhibitors, are addressed prior to treatment.
A physician-supervised test dose (1 to 3 mg/kg ibogaine equivalent) is administered 24 to 48 hours before the primary flood dose to assess individual sensitivity, confirm absence of immediate adverse reaction, and calibrate the flood dose calculation.
Cardiac risk is real. Ibogaine , in both TA and HCl form, has been associated with deaths in inadequately screened or improperly monitored patients. MindScape's monitoring protocol exists because ibogaine demands it. Do not pursue ibogaine treatment at any facility that does not require pre-treatment ECG, baseline QTc assessment, and continuous cardiac monitoring throughout the acute phase.
The answer is not a general rule. it is a clinical determination made by the MindScape medical team based on your specific case. Formulation selection integrates four key variables: your primary indication, your cardiac profile, your CYP2D6 metabolizer status, and your treatment goals.
Some patients are best served by TA alone. the extended duration and alkaloid synergy drive the depth of transformation sought in complex trauma, Parkinson's, and spiritual protocols. Others are best served by HCl alone. particularly those with cardiac risk factors or those pursuing a focused opioid detoxification where pharmacokinetic precision is the priority.
Many MindScape patients receive both. a TA flood with HCl booster, or a primary HCl session followed by a TA session in a subsequent visit as the treatment relationship deepens. There is no one-size answer. There is only the right answer for you.
Start Your PrescreenFormulation Decision Factors
Primary indication
OUD, PTSD, depression, Parkinson's, TBI, alcohol, each indication has a preferred formulation based on clinical evidence and MindScape protocol data.
Cardiac profile
Baseline QTc, prior arrhythmia history, current medications, and structural cardiac conditions. Elevated cardiac risk shifts preference toward HCl's well-characterized single-molecule profile.
CYP2D6 metabolizer status
Poor metabolizers (7 to 10% of population) require significant dose reduction for both formulations. This must be established before treatment, not inferred from experience.
Treatment goals
Targeted withdrawal interruption favors HCl precision. Deep transformational or neurological protocols often benefit from TA's extended duration and alkaloid synergy.
Prior ibogaine experience
Patients with documented TA or HCl response data from previous treatments guide re-dosing strategy and formulation choice for follow-up sessions.